| The announcement was made after market hours yesterday, 18 January 2017. Meanwhile, the BSE Sensex was up 7.26 points, or 0.03%, to 27,264.90. On the BSE, so far 3,742 shares were traded in the counter, compared with average daily volumes of 1.03 lakh shares in the past one quarter. The stock had hit a high of Rs 585 and a low of Rs 581.15 so far during the day. The stock hit a 52-week high of Rs 617.70 on 23 September 2016. The stock hit a 52-week low of Rs 458.25 on 25 May 2016. The stock had underperformed the market over the past 30 days till 18 January 2017, rising 3.49% compared with the 3.61% rise in the Sensex. The scrip had, however, outperformed the market in past one quarter, falling 2.26% as against Sensex's 3.10% decline. The large-cap company has equity capital of Rs 160.88 crore. Face value per share is Rs 2. Cipla announced that its wholly-owned subsidiary Goldencross Pharma has entered in to a definitive agreement to sell its 100% equity stake in Four M Propack, India (Four M Propack) to Shriji Polymers (India) (Shriji Polymers) for a consideration of Rs 13.50 crore and an additional sum derived on the basis of the value of mutual funds, cash and bank balance, tax refunds, etc. at the time of closing estimated at around Rs 5.70 crore. Shriji Polymers is engaged in the business of manufacturing of HDPE bottles and PP caps for the pharmaceutical industry. The turnover of Four M Propack for the financial year ended 31 March 2016 was Rs 9.77 crore which is entirely on account of sales to the company. The net worth of Four M Propack as on 31 March 2016 was Rs 15.82 crore constituting 0.001% of the consolidated net worth of the company. The transaction is expected to be completed within 45 days from date of signing of the definitive agreement, subject to completion of certain condition precedent and receipt of applicable approvals. Cipla said that none of the persons belonging to promoter/promoter Group(s) of the company has any interest in the transaction and it is not a related party transaction for the company. On a consolidated basis, Cipla's net profit dropped 34.75% to Rs 354.34 crore on 8.66% rise in net sales to Rs 3671.88 crore in Q2 September 2016 over Q2 September 2015. Cipla is a global pharmaceutical company. Its portfolio includes over 1,000 products across wide range of therapeutic categories with one quality standard globally. Powered by Capital Market - Live News |